Clare Cruickshank

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

David P. Dearnaley, Isabel Syndikus, Helen Mossop et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas Brand, Alison Tree, Peter Ostler et al. · The Lancet Oncology · 2019 · 519 citations · Full text

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Anna Wilkins, Helen Mossop, Isabel Syndikus et al. · The Lancet Oncology · 2015 · 149 citations · Full text

A Phase I Study of Single Administration of Antibody-Directed Enzyme Prodrug Therapy with the Recombinant Anti–Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein MFECP1 and a Bis-Iodo Phenol Mustard Prodrug

Astrid Mayer, Roslyn J. Francis, Surinder K. Sharma et al. · Clinical Cancer Research · 2006 · 80 citations

Nanotherapeutics, Prodrug Activation, Immunology +19

PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018)

Isabel Syndikus, Clare Cruickshank, John Staffurth et al. · Clinical and Translational Radiation Oncology · 2020 · 49 citations · Full text